NCT07489612Enrolling by invitationPhase 2
QLS1410 in Participants With Uncontrolled Hypertension
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of QLS1410 in Participants With Uncontrolled Hypertension
Source: ClinicalTrials.gov · Last updated 22 May 2026
Brief summary (registry, in English)
The goal of this clinical trial is to measure the efficacy and safety of QLS1410 in participants with uncontrolled hypertension (uHTN) or treatment-resistant hypertension (rHTN). The main objective is to compare the difference in systolic blood pressure（SBP) change from baseline at Week 12 of treatment between participants receiving QLS1410 tablets and participants receiving placebo tablets.
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 260 (estimated)
- First submitted
- 18 Mar 2026
- Start date
- Apr 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.
- Diseases
- High blood pressure
- NCT number
- NCT07489612
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 260
- From Apr 2026 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Has the following known secondary causes of hypertension: renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation.
- NYHA functional heart failure class IV at Screening.
Lab values
- Serum potassium (K+) level \<3.5 and ≥ 5.0 mmol/L.
Other
- Mean seated systolic blood pressure (SBP)≥ 180 mmHg.
- Mean seated diastolic blood pressure (DBP)≥ 110 mmHg.
- Estimated glomerular filtration rate \< 45 mL/min/1.73m2.
Who the study is looking for
- Male or female participants must be ≥ 18 years old.
- Mean seated SBP ≥ 140 mmHg at Screening and at Baseline..
- Fulfil at least 1 of the following 2 criteria:
- Uncontrolled Hypertension (uHTN) subpopulation: have a stable regimen (≥ 4 weeks) of 2 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the Investigator.
- Resistant Hypertension (rHTN) subpopulation: have a stable regimen (≥ 4 weeks) of ≥ 3 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the Investigator.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Qilu Hospital of Shandong University Coordinator of this site? Confirm its status | Jinan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.